Infectious Diseases in Critical Care Medicine

the nonantibiotic causes of apparent antibiotic failure should also be considered, i.e.,
myocardial abscess, noncardiac septic foci. The usual dose of daptomycin for bacteremia/
ABE is 6 mg/kg (IV) q 24 h (with normal renal function), but the dose of daptomycin may be
safely increased if the patient is not responding to daptomycin or other anti-staphylococcal
antibiotics. Daptomycin given at a dose of 12 mg/kg (IV) q 24 h (with normal renal function)
has been used safely without side effects for over four weeks of therapy. If persistent fever is
related to a myocardial/paravalvular abscess, or device related, then surgical drainage/valve
replacement may be needed to control/eradicate the infection (62–68).

REFERENCES

1. Cunha BA. Intravenous line onfections. Crit Care Clin 1998; 8:339–346.


2. Sherertz RJ. Update on vascular catheter infections. Curr Opin Infect Dis 2004; 17:303–307.


3. Siefert H, Jansen B, Farr BM. Catheter-Related Infections. 2nd ed. New York: Marcel Dekker; 2004.


4. Maki DG. Infections caused by intravascular devices used for infusion therapy: pathogenesis,
   prevention, and management. Infections Associated with Indwelling Medical Devices. 2nd ed.
   Washington: American Society for Microbiology; 1994.


5. Johnson A, Oppenheim BA. Vascular catheter-related sepsis: diagnosis and prevention. J Hosp Infect
   1992; 20:67–78.


6. Toltzis P, Goldman DA. Current issues in central venous catheter infection. Annu Rev Med 1990;
   41:169–176.


7. Corona ML, Peters SG, Narr BJ, et al. Infections related to central venous catheters. Mayo Clin Proc
   1990; 65:979–986.


8. Sitges-Serra A, Pi-Suner T, Garces JM, et al. Pathogenesis and prevention of catheter-related
   septicemia. Am J Infect Control 1995; 23: 310–316.


9. Norwood S, Ruby A, Civetta J, et al. Catheter-related infections and associated septicemia. Chest 1991;
   99:968–975.


10. Farr BM, Hanna H, Raad I. Nosocomial infections related to use of intravascular devices inserted for
    long term vascular access. In: Mayhall G, ed. Hospital Epidemiology and Infection Control. 3rd ed.
    Baltimore, MD: Lippincott; Williams & Wilkins: 2004.


11. Mermal LA, Allon M, Bouza E, et al. Clinical Practice Guidelines for the Diagnosis and Management
    of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of
    America. Clinical Infect Dis 2009; 49:1–54.


12. Raad I, Bodey GP. Infectious complications of indwelling long-term central venous catheters. Infect
    Dis 1992; 15:197–210.


13. Early TF, Gregory RT, Wheeler JR, et al. Increased infection rate in double lumen versus single lumen
    Hickman catheters in cancer patients. South Med J 1990; 83:34–36.


14. Ullman RF, Gurevich I, Schoch PE, et al. Colonization and bacteremia related to duration of triple-
    lumen intravascular catheter placement. Am J Infect Control 1990; 18:201–207.


15. Arnow PM, Quimosing EM, Beach M. Consequences of intravascular catheter sepsis. Clin Infect Dis
    1993; 16:778–784.


16. Maki DG, Weise CE, Sarafin HW. A semiquantitative culture method for identifying intravenous-
    catheter-related infection. N Engl J Med 1977; 296:1305–1309.


17. Klouche M, Schroder U. Rapid methods for diagnosis of bloodstream infections. Clin Chem Lab Med
    2008; 46:888–908.


18. Fatkenheuer G, Preuss M, Salzberger B, et al. Long term outcome and quality of care patients with
    Staphylococcus aureusbacteremia. Eur J Clin Microbiol Infect Dis 2004; 23:157–162.


19. Kim SH, Park WB, Lee KD, et al. Outcome ofStaphylococcus aureusbacteremia in patients with
    eradicable foci versus noneradicable foci. Clin Infect Dis 2003; 37:794–797.


20. Mylotte JM, McDermott C.Staphylococcus aureusbacteremia caused by infected intravenous catheters.
    Am J Infect Control 1987; 15:1–6.


21. Malanoski GJ, Samore MH, Pefanis A, et al.Staphylococcus aureuscatheter-associated bacteremia. Arch
    Intern Med 1995; 155:1161–1166.


22. Jensen AG. Importance of focus identification in the treatment ofStaphylococcus aureusbacteremia.
    J Hosp Infect 2002; 52:29–36.


23. Finkelstein R, Sobel JD, Nagler A, et al.Staphylococcus aureusbacteremia and endocarditis: comparison
    of nosocomial and community-acquired infection. J Med 1984; 15:193–211.


24. Lesens O, Hansmann Y, Storck D, et al. Risk factors for metastatic infection in patients with
    Staphylococcus aureusbacteremia with and without endocarditis. Eur J Intern Med 2003; 14:227–231.

Intravenous Central Line Infections in Critical Care 215